| Literature DB >> 34707660 |
Aishath Maharath1, Mariyam Shabeena Ahmed2.
Abstract
BACKGROUND: Bloodstream infections pose a significant health problem worldwide and is a major cause of morbidity and mortality in many countries. It is important to have country-specific data for major pathogens causing bloodstream infections, in light of emerging resistance patterns of common bacterial isolates. Due to the scarcity of reports in this area, the aim of this study was to identify bacterial pathogens causing bloodstream infections among the study population.Entities:
Year: 2021 PMID: 34707660 PMCID: PMC8545585 DOI: 10.1155/2021/3088202
Source DB: PubMed Journal: Int J Microbiol
Trends in the organisms isolated from the culture-positive patient samples.
| Organisms | Bacterial isolate (%) | Paediatric ( | Adult ( | ||
|---|---|---|---|---|---|
| Male ( | Female ( | Male ( | Female ( | ||
| Gram-positive | 338 (71.8) | 68 (85.0) | 39 (78.0) | 136 (68.7) | 95 (66.4) |
| Gram-negative | 133 (28.2) | 12 (15.0) | 11 (22) | 62 (31.3) | 48 (33.6) |
Distribution of organism isolated from blood culture samples during the two years.
| Bacterial isolates | Number (%) | Year | |
|---|---|---|---|
| 2016 | 2017 | ||
|
| 23 (4.9) | 14 (5.9) | 9 (3.9) |
| Coagulase-negative | 246 (52.2) | 128 (53.6) | 118 (50.9) |
|
| 62 (13.2) | 38 (15.9) | 24 (10.3) |
|
| 7 (1.5) | 3 (1.3) | 4 (1.7) |
|
| 63 (13.4) | 25 (10.5) | 38 (16.4) |
|
| 7 (1.5) | 4 (1.7) | 3 (1.3) |
|
| 5 (1.1) | 3 (1.3) | 2 (0.9) |
|
| 12 (2.5) | 4 (1.7) | 8 (3.4) |
|
| 42 (8.9) | 17 (7.1) | 25 (10.8) |
|
| 4 (0.8) | 3 (1.3) | 1 (0.4) |
| Total | 471 | 239 | 232 |
Trends of Gram-positive and Gram-negative bacterial isolates.
| Number (%) | 2016 ( | 2017 ( |
|
| |
|---|---|---|---|---|---|
| Gram-positive | 338 (71.8) | 183 (76.6) | 155 (66.8) | 5.533 | 0.019 |
| Gram-negative | 133 (28.2) | 56 (23.4) | 77 (33.2) |
Trends of bacterial isolates among paediatric and adult populations, n=(471).
| Bacterial isolates | Number (%) | Paediatric patients ( | Adult patients ( |
| ||
|---|---|---|---|---|---|---|
| 2016 ( | 2017 ( | 2016 ( | 2017 ( | |||
| Gram-positive isolates | 338 (71.8%) | 61 (81.3) | 46 (83.6) | 122 (74.4) | 109 (61.6) | |
|
| 23 (4.9) | 8 (10.7) | 5 (9.1) | 6 (3.7) | 4 (2.3) | 0.940 |
| Coagulase-negative | 246 (52.2) | 49 (65.3) | 35 (63.6) | 79 (48.2) | 83 (46.9) | 0.154 |
|
| 62 (13.2) | 3 (4.0) | 6 (10.9) | 35 (21.3) | 18 (10.2) | 0.063 |
|
| 7 (1.5) | 1 (1.3) | 0 (0.0) | 2 (1.2) | 4 (2.3) | 0.212 |
| Gram-negative isolates | 133 (28.2) | 14 (18.7) | 9 (16.4) | 42 (25.6) | 68 (38.4) | |
|
| 63 (13.4) | 6 (8.0) | 6 (10.9) | 19 (11.6) | 32 (18.1) | 0.417 |
|
| 7 (1.5) | 4 (5.3) | 3 (5.5) | 4 (2.4) | 3 (1.7) | — |
|
| 5 (1.1) | 1 (1.3) | 0 (0.0) | 2 (1.2) | 2 (1.1) | 0.361 |
|
| 12 (2.5) | 3 (4.0) | 1 (1.8) | 1 (0.6) | 7 (4.0) | 0.030 |
|
| 42 (8.9) | 3 (4.0) | 1 (1.8) | 14 (8.5) | 24 (13.6) | 0.139 |
|
| 4 (0.8) | 1 (1.3) | 1 (1.8) | 2 (1.2) | 0 (0.0) | 0.248 |
Trends of group of patients associated with BSI.
| Patient group | Number (%) | 2016 ( | 2017 ( |
|
|
|---|---|---|---|---|---|
| Paediatric | 130(27.6) | 75(31.4) | 55(23.7) | 3.469 | 0.063 |
| Adult | 341(72.4) | 164(68.7) | 177(76.2) |
Trends of BSI among various group of patients
| Patient group | Age category | Age group | Number (%) | 2016 ( | 2017 ( |
|
|---|---|---|---|---|---|---|
| Paediatrics | Neonates | <28 days | 71 (15.1) | 44 (18.4) | 27 (11.6) | 0.549 |
| Infants | >28 days to 1 year | 21 (4.5) | 11 (4.6) | 10 (4.3) | 0.223 | |
| Children | 1–15 years | 38 (8.1) | 20 (8.4) | 18 (7.8) | 0.239 | |
|
| ||||||
| Adults | Adults | 16–65 years | 163 (34.6) | 76 (31.8) | 89 (38.4) |
|
| Elderly | >65 years | 176 (37.4) | 88 (36.9) | 88 (37.9) | 0.589 | |
Note: p values in bold indicate significant effects.
Antimicrobial resistance of Gram-positive isolates among paediatric and adult patients over the two years.
| Antimicrobial agents |
|
| Coagulase-negative |
|
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance (%) | Resistance (%) | Resistance (%) | Resistance (%) | |||||||||||||||||
| 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | |||||||||||||
| Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | Paediatric | Adult | |||||
| Ampicillin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | 36 (73) | 57 (72) | 21 (62) | 64 (77) |
| 3 (100) | 29 (85) | 6 (100) | 13 (76) |
| 0 (0) | 0 (0) | — | 0(0) | — |
| Piperacillin/tazobactam | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | 0 (0) | 1 (7) | 0 (0) | — | — | 0 (0) | 0 (0) | — | — | — | 0 (0) | 0 (0) | — | 0(0) | — |
| Cloxacillin | 0 (0) | 0 (0) | — | 0 (0) | — | 6 (16) | 8 (15) | 1 (7) | 3 (11) | 0.535 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | — | — | — | - | — |
| Cephalexin | 0 (0) | 1 (20) | 1 (20) | 0 (0) | — | 9 (19) | 30 (40) | 8 (25) | 28 (37) |
| 1 (33) | 12 (39) | 1 (17) | 7 (47) |
| 1 (100) | 1 (50) | — | 2(67) | 0.073 |
| Cefuroxime | 0 (0) | 0 (0) | — | — | — | 1 (50) | 0 (0) | 0 (0) | — | — | — | — | — | 1 (50) | — | — | — | — | — | — |
| Cefotaxime | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | 9 (20) | 25 (42) | 8 (25) | 24 (32) |
| 1 (50) | 9 (29) | 1 (17) | 4 (29) | 0.363 | 1 (100) | 0 (0) | — | — | — |
| Ceftazidime | — | — | — | — | — | — | — | 2 (100) | — | — | — | — | — | — | — | — | — | — | — | — |
| Ceftriaxone | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | 1 (50) | 3 (42) | 0 (0) | 1 (100) | 0.835 | — | 1 (100) | — | 1 (100) | - | - | 0 (0) | - | - | - |
| Cefepime | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Vancomycin | — | — | — | — | — | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | — | 0 (0) | — | 0(0) | — | — | — | — | — | — |
| Gentamicin | 4 (57) | 3 (75) | 1 (50) | 0 (0) |
| 9 (21) | 23 (36) | 8 (35) | 12 (26) |
| 0 (0) | 4 (15) | 0 (0) | 1(11) | - | 1(100) | 1(50) | - | 2(67) | 0.073 |
| Tobramycin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Amikacin | — | 1 (100) | — | — | — | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — | 0 (0) | 0 (0) | 0 (0) | 0(0) | — | — | — | — | 1(100) | — |
| Netilmicin | — | — | — | — | — | — | 0 (0) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Ciprofloxacin | 0 (0) | 1 (25) | 2 (40) | 1 (25) | — | 9 (21) | 25 (38) | 7 (23) | 20 (27) | — | 1 (33) | 10 (37) | 0 (0) | 6(40) |
| 1(100) | 1(50) | — | 2(67) | 0.073 |
| Cotrimoxazole | 3 (50) | 2 (40) | 1 (50) | 3 (75) | 0.295 | 10 (22) | 22 (30) | 4 (13) | 12 (18) |
| 0 (0) | 3 (10) | 0 (0) | 1(7) | — | 1(100) | 1(50) | — | 1(100) | 0.667 |
Note: p values in bold indicate significant effects.
Antimicrobial resistance pattern of Gram-positive isolates among two-year study period.
| Antimicrobial agents |
| Coagulase-negative |
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance (%) |
| Resistance (%) |
| Resistance (%) |
| Resistance (%) |
| |||||
| 2016 ( | 2017 ( | 2016 ( | 2017 ( | 2016 ( | 2017 ( | 2016 ( | 2017 ( | |||||
| Ampicillin | 0 (0) | 0 (0) | — | 93 (73) | 85 (73) | 0.999 | 32 (86) | 19 (83) |
| 0 (0) | 0 (0) | — |
| Piperacillin/tazobactam | 0 (0) | 0 (0) | — | 1 (5) | 0 (0) | 0.826 | 0 (0) | — | — | 0 (0) | 0 (0) | — |
| Cloxacillin | 0 (0) | 0 (0) | — | 14 (16) | 4 (10) | 0.695 | 0 (0) | 0 (0) | — | — | — | — |
| Cephalexin | 1 (8) | 1 (11) | 0.675 | 39 (32) | 36 (34) | 0.788 | 13 (38) | 8 (38) | 0.162 | 2 (67) | 2 (67) | 1.000 |
| Cefuroxime | 0 (0) | — | — | 1 (33) | 0 (0) | 0.667 | — | 1(50) | — | — | — | — |
| Cefotaxime | 0 (0) | 0 (0) | — | 34 (33) | 32 (30) | 0.628 | 10 (30) | 5 (25) | 0.495 | 1(50) | — | — |
| Ceftazidime | — | — | — | — | 2(100) | — | — | — | — | — | — | — |
| Ceftriaxone | 0 (0) | 0 (0) | — | 4 (44) | 1 (50) | 0.050 | 1 (100) | 1 (100) | — | 0(0) | — | — |
| Cefepime | — | — | — | — | — | — | — | — | — | — | — | — |
| Vancomycin | — | — | — | 0 (0) | 0 (0) | — | 0 (0) | 0 (0) | — | — | — | — |
| Gentamicin | 7 (64) | 1 (33) | 0.376 | 32 (30) | 20 (28) | 0.835 | 4 (13) | 1 (8) | 0.664 | 2 (67) | 2 (67) | 1.000 |
| Tobramycin | — | — | — | — | — | — | — | — | — | — | — | — |
| Amikacin | 1(100) | — | — | 0 (0) | 0(0) | — | 0 (0) | 0 (0) | — | — | 1 (100) | — |
| Netilmicin | — | — | — | 0 (0) | — | — | — | — | — | — | — | — |
| Ciprofloxacin | 1 (10) | 3 (33) | 0.216 | 34 (32) | 27 (26) | 0.377 | 11 (37) | 6 (29) | 0.538 | 2 (67) | 2 (67) | 1.000 |
| Cotrimoxazole | 5 (45) | 4 (67) | 0.078 | 32 (27) | 16 (16) | 0.063 | 3 (9) | 1(5) | 0.957 | 2 (67) | 1 (100) | 0.071 |
n = bacterial isolates among patients tested. Note: p values in bold indicate significant effects.
Antimicrobial resistance pattern of Gram-negative isolates among two-year study period.
| Antimicrobial agents |
| Acinetobacter spp. ( |
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance (%) | Resistance (%) | Resistance (%) | Resistance (%) | Resistance (%) | Resistance (%) | |||||||||||||
| 2016 ( | 2017 ( |
| 2016 ( | 2017 ( |
| 2016 ( | 2017 ( |
| 2016 ( | 2017 ( |
| 2016 ( | 2017 ( |
| 2016 ( | 2017 ( |
| |
| Ampicillin | 24(96) | 36(97) |
| 4(100) | 3(100) | — | — | — | — | — | — | — | 13(76) | 21(84) |
| 1(33) | 0(0) | 0.667 |
| Ampicillin/sulbactam | 1(100) | 15(100) |
| — | 0(0) | — | — | — | — | — | — | — | — | 1(100) | — | — | — | — |
| Augmentin | — | 22(61) | — | — | 1(100) | — | — | — | — | — | — | — | — | 3(13) | — | — | 0(0) | — |
| Piperacillin/tazobactam | 3(100) | 13(87) |
| 3(100) | 1(100) | — | 0(0) | — | — | 0(0) | — | — | — | 1(100) | — | — | — | — |
| Cephalexin | 19 (82) | 30 (83) |
| 4 (100) | 1 (100) | — | — | — | — | — | — | — | 9(69) | 13(59) |
| — | (0)0 | — |
| Cefuroxime | 84 | 76 |
| 75 | 33 | 0.541 | — | — | — | 100 | — | — | 71 | 60 |
| 0 | 0 | — |
| Cefotaxime | 67 | 75 |
| 75 | 100 |
| 0 | — | — | 0 | — | — | 60 | 57 |
| — | 0 | — |
| Ceftazidime | 50 | 58 | 0.158 | 75 | 33 | 0.541 | 33 | 0 | 0.495 | 0 | 0 | — | 31 | 12 |
| — | 0 | — |
| Ceftriaxone | 68 | 70 |
| 75 | 100 |
| 0 | — | — | 0 | — | — | 65 | 57 |
| 0 | 0 | — |
| Cefepime | 100 | 94 |
| 100 | 100 | — | 0 | — | — | 0 | — | — | — | 100 | — | — | — | — |
| Imipenem | 33 | 38 | 0.067 | 33 | 100 | 0.056 | 0 | — | — | 0 | — | — | — | 100 | — | — | — | — |
| Meropenem | 25 | 93 | 0.604 | 100 | 100 | — | — | — | — | — | — | — | — | 100 | — | — | — | — |
| Gentamicin | 55 | 47 | 0.656 | 75 | 100 |
| 33 | 50 | 0.995 | 33 | 25 | 0.704 | 20 | 8 | 0.320 | — | — | — |
| Tobramycin | — | — | — | — | — | — | 33 | 50 | 0.995 | 0 | 25 | 0.389 | — | — | — | — | — | — |
| Amikacin | 20 | 39 | 0.338 | 75 | 33 | 0.541 | 33 | 50 | 0.995 | 33 | 0 | 0.104 | 0 | 8 | 0.242 | 0 | 0 | — |
| Netilmicin | 29 | 45 | 0.685 | 75 | 33 | 0.541 | 33 | 50 | 0.995 | 33 | 0 | 0.104 | 6 | 8 | 0.934 | — | 0 | — |
| Ciprofloxacin | 59 | 60 |
| 75 | 100 |
| 33 | 0 | 0.495 | 0 | 25 | 0.389 | 50 | 41 |
| 0 | 0 | — |
| Cotrimoxazole | 50 | — | — | — | — | — | — | — | — | — | — | — | 50 | 100 | 0.333 | — | — | — |
| Colistin | 0 | 7 | 0.668 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
n = bacterial isolates among patients tested. Note: p values in bold indicate significant effects.
Multidrug resistance (MDR) isolates for the two-year study period.
| Bacterial isolates | Number (%) | Year |
| |
|---|---|---|---|---|
| 2016 | 2017 | |||
| Coagulase-negative | 62 (45.2) | 37 (52.1) | 25 (37.8) |
|
|
| 10 (7.2) | 8 (11.2) | 2 (3.0) |
|
|
| 4 (3.0) | 2 (2.8) | 2 (3.0) | 0.182 |
|
| 43 (31.3) | 15 (21.1) | 28 (42.4) |
|
|
| 4 (3.0) | 3(4.2) | 1 (1.5) | 0.194 |
|
| 1 (0.7) | 1 (1.4) | 0 (0.0) | — |
|
| 13 (10.0) | 5 (7.0) | 8 (12.1) |
|
| Total MDR isolates | 137 | 71 | 66 | |
Note: p values in bold indicate significant effects.